Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance

Vildagliptin is one of the most extensively studied dipeptidyl peptidase-4 (DPP-4) inhibitors in terms of its clinical utility. Over the last decade, a vast panorama of evidence on the benefit–risk profile of vildagliptin has been generated in patients with type 2 diabetes mellitus (T2DM). In this a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mathieu, Chantal, Kozlovski, Plamen, Paldánius, Päivi M, Foley, James E, Modgill, Vikas, Evans, Marc, Serban, Carmen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Type 2 Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813467/
https://www.ncbi.nlm.nih.gov/pubmed/29632610
http://dx.doi.org/10.17925/EE.2017.13.02.68

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813467/
https://www.ncbi.nlm.nih.gov/pubmed/29632610
http://dx.doi.org/10.17925/EE.2017.13.02.68

Ejemplares similares